About
Precision Epigenomics develops EPISEEK, a blood-based multi-cancer detection test that identifies over 60 cancer types through analysis of circulating tumor DNA and epigenomic modifications. The test detects hypermethylated DNA regions—patterns consistently altered across multiple cancer types—providing early detection before symptoms appear. Results are delivered in 7-10 days, and the company offers support for follow-up imaging costs up to $2,000 when financial barriers exist.
The EPISEEK approach prioritizes accessibility and reliability over invasive procedures. Rather than requiring tissue biopsies or advanced imaging, the test uses a simple blood draw analyzed through proprietary software to generate a report indicating either an abnormal methylation signal or no cancer signal detected. The company positions the test as more specific than imaging while remaining more accessible than traditional diagnostic methods.
Precision Epigenomics serves multiple audiences: healthcare providers seeking advanced diagnostic tools, oncologists and general practitioners integrating cancer screening into patient care, and employers or wellness programs enhancing employee health benefits. The company emphasizes that early detection is critical for cancer treatment outcomes, and the test screens for the top 10 leading causes of cancer-related deaths including brain cancer, lung cancer, breast cancer, prostate cancer, and pancreatic cancer.
Longevity Contribution
- Detects over 60 cancer types from a single blood draw, including hard-to-diagnose malignancies like brain cancer
- Analyzes epigenomic modifications (hypermethylated DNA loci) rather than relying solely on circulating tumor DNA quantity
- Delivers results in 7-10 days with proprietary software analysis
- Covers up to $2,000 of follow-up imaging costs when financial barriers exist for patients with positive results